|
ANTICOAGULATION (ORAL) Definition: To reduce the risk of thromboembolic events when certain risks or conditions are present. |
||
|
Indication |
|
Duration |
|
Atrial fibrillation or flutter |
2.0-3.0 |
Indefinite to age 80 or with history of peripheral embolism or CVA - > age 80 and without these risks use ASA mg/d |
|
Cardiomyopathy with EF < 25% |
2.0-3.0 |
Indefinite – weigh against risk of bleeding from falls |
|
DVT/PE – 1st episode |
2.0-3.0 |
3-6 months if reversible or time-limited risk > 6 months if idiopathic |
|
DVT/PE – recurrent or continuing risk factor (pelvic malignancy, blood dyscrasia) |
2.0-3.0 |
Indefinite |
|
Mechanical heart valve |
2.5-3.5 |
Indefinite – add ASA 81 mg/d if high embolic risk |
|
MI (following acute MI) |
2.0-3.0 |
3 months then ASA 162-325 mg/d indefinitely |
|
Valvular heart disease with history SE |
2.0-3.0 |
Indefinite – add ASA 81 mg/d if systemic embolism occurs on Warfarin |
|
References: Geriatrics At Your Fingertips, 2000 Edition, p. 31. JAGS, Clinical Practice Guidelines, 48:224-227, 2000. 10.03 |
||